Polo-like kinase 1 (PLK1) induces Vemurafenib resistance in melanoma.

Polo-like kinase 1 (PLK1) induces Vemurafenib resistance in melanoma.

<p><b>(A)</b> Relative cell viability under the treatment of Vemurafenib in mouse melanoma cells (mMC) and mouse melanoma with Plk1 knock-in (mMPI) cells. <i>n</i> = 3 biological replicates. Mean ± SD. n.s., <i>P</i> > 0.05; * <i>P</i> < 0....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile nagusia: Fengyi Mao (15073242) (author)
Beste egile batzuk: Sai Wu (6096290) (author), Derek B. Allison (15141675) (author), Daheng He (9189701) (author), Yifan Kong (4458616) (author), Chaohao Li (15141681) (author), Zhiguo Li (431917) (author), Yanquan Zhang (14930570) (author), Xinyi Wang (559030) (author), Qiongsi Zhang (2818111) (author), Chi Wang (131921) (author), Xiaoqi Liu (45630) (author)
Argitaratua: 2025
Gaiak:
Cell Biology
Genetics
Molecular Biology
Developmental Biology
Cancer
Hematology
Biological Sciences not elsewhere classified
suppress tumor growth
like kinase 1
crucial transcription factor
cnc homolog 1
clinical database analysis
shortened mice survival
>< sup ><
div >< p
cutaneous melanoma based
v600e </ sup
patient survival
pten </
ca </
></ sup
synergistic efficiency
novel function
negatively correlates
genes involved
cell cycle
cancer progression
cancer metabolism
bach1 ),
>- deficiency
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak